Compare HCI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCI | PHVS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | HCI | PHVS |
|---|---|---|
| Price | $188.14 | $23.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $230.00 | $39.44 |
| AVG Volume (30 Days) | 164.0K | ★ 546.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 32.29 | N/A |
| EPS | ★ 15.80 | N/A |
| Revenue | ★ $816,578,000.00 | N/A |
| Revenue This Year | $19.65 | N/A |
| Revenue Next Year | $9.97 | N/A |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $106.89 | $11.51 |
| 52 Week High | $210.50 | $29.80 |
| Indicator | HCI | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 47.33 |
| Support Level | $183.33 | $23.61 |
| Resistance Level | $190.46 | $25.44 |
| Average True Range (ATR) | 5.67 | 1.95 |
| MACD | 2.13 | -0.31 |
| Stochastic Oscillator | 93.68 | 13.24 |
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.